Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance

Citations Over TimeTop 1% of 2002 papers

Abstract

The relation between human papillomavirus type 16 (HPV 16) viral load in cervical scrapes and development of high-grade cervical intraepithelial neoplasia (CIN II or III) was studied in a nested case-control study of women with normal cytology (group A) and in a cohort of women with abnormal cytology (group B). HPV 16 DNA load was determined using a quantitative real-time PCR assay. In group A, case women (women with CIN II/III, n = 12) had a significantly higher viral load than control women (women with CIN < or = I, n = 47). This resulted in an increased relative risk of women with the 50% highest viral load for development of CIN II/III (OR 7.7; CI 1.6-33). In group B, women with CIN II/III (n = 38) had a significantly higher viral load than women with CIN < or = I (n = 25). Women with the 50% highest viral load had an increased relative risk of CIN II/III (OR 3.2; CI 1.1-9.3) and a decreased chance of both viral clearance and cytologic regression. Our data suggest that in women with normal cytology an increased HPV 16 load confers an increased risk of developing a CIN lesion. A sustained high viral load is subsequently informative for progression to a high-grade CIN lesion.

Related Papers

• → Elevated neutrophil–lymphocyte ratio can be a biomarker for predicting the development of cervical intraepithelial neoplasia(2021)18 cited
• → High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing(2007)29 cited
• → Risk of Cervical Intraepithelial Neoplasia Grade 2 or 3 after Loop Electrosurgical Excision Procedure Associated with Human Papillomavirus Type 16 Variants(2007)19 cited
• Relationships of Human Papillomavirus Infection and Expression of P53,MDM2 proteins in Cervical Intra-epithelial Neoplasia(2006)
• → The specific features of cervical intraepithelial neoplasia associated with persistent HPV infection(2019)